Paris, February 2, 2010 – André Choulika, Chief Executive Officer of Cellectis
S.A. (Alternext: ALCLS), the French genome engineering specialist, will present a
corporate update at the 12th Annual BIO CEO & Investor Conference on Monday 8
February, at 3.30 PM EST (Eastern Standard Time), in the Conrad room at the
Waldorf Astoria Hotel in New York, USA.
A live audio webcast of the presentation will be available at
http://www.veracast.com/webcasts/bio/ceoinvestor2010/23113132.cfm. An archive
of the presentation will be accessible at the same address one hour after the
event, until 11 May 2010.
The BIO CEO & Investor Conference is the largest investor conference focused on
publicly traded biotech companies.
About Cellectis S.A.
Cellectis SA is a world leader in genome engineering and genome surgery. The company
focuses on developing and producing custom meganucleases for use in in vivo genome
surgery addressing the therapeutic, food processing, bioproduction and research sectors.
Worldwide, Cellectis has entered into more than 50 agreements with major players in the
pharmaceutical, biotechnology and agrobiotechnology industries, and has over 20
collaborations with academic research groups. To date, Cellectis has raised over €70
million in both equity operations and public financing and is listed on the NYSE-Euronext
Alternext market (ticker code: ALCLS). For further information about Cellectis, visit our
website: www.cellectis.com
